Eilean Therapeutics  announced the upcoming presentation of preclinical data for its first-in-class, wild-type–sparing JAK2-JH2/V617F inhibitor ZE74-0282 at the 67th American Society of Hematology (ASH) Annual Meeting. The company also confirmed plans to initiate first-in-human clinical studies in December 2025.

Eilean Therapeutics  announced the presentation of in vivo data for its first-in-class MALT1 degrader, TE205, as a disease-modifying therapy for ulcerative colitis at the 4th International Conference on Microbiology and Immunology in Las Vegas, Nevada.

Eilean Therapeutics  today announced the presentation of preclinical data for its novel, brain-permeable CDK2 inhibitor at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

Eilean Therapeutics LLC today announced the presentation of data for its brain- and lung-permeable pan-EGFR inhibitor, ZE77-0273 is a reversible small-molecule drug candidate that demonstrates broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer (NSCLC), a high selectivity index versus wild-type EGFR, and a wide therapeutic window characterized by excellent safety and tolerability.

Eilean Therapeutics LLC, a biopharmaceutical company targeting escape mutations in hematologic and solid malignancies, today announced that an abstract related to the company’s first-in-class oral MALT1 degrader has been accepted for a poster presentation at the upcoming American Society of Hematology (ASH) Annual Meeting.

Eilean Therapeutics AU Pty Ltd, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, has joined The Leukemia & Lymphoma Society (LLS) in the groundbreaking collaborative Beat AML® Master Clinical Trial.

Eilean Therapeutics LLC, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the IND for lomonitinib (ZE46-0134), allowing the company to proceed with a Phase 1 clinical trial in FLT3 mutated relapsed/refractory (R/R) AML.

Eilean Therapeutics LLC announces the clearance from the Human Research Ethics Committee in Australia for lomonitinib (ZE46-0134) allowing the company to proceed with a Phase I clinical trial in relapsed/refractory (R/R) AML.

Eilean Therapeutics Australia Pty, Ltd, received clearance from the Human Research Ethics Committee in Australia to begin a Phase 1 trial of balamenib (ZE63-0302).

Eilean Therapeutics LLC announced the acquisition of Ness Therapeutics Inc (Ness) in an all-equity transaction.

Eilean Therapeutics LLC today announced the clearance from the Human Research Ethics Committee in Australia to begin human dosing in the Phase 1 clinical program of eiletoclax, a highly potent and selective BCL2 inhibitor.

Eilean Therapeutics LLC, today announced the completion of a single ascending dose Phase 1 clinical study of lomonitinib and initiation of a multiple ascending dose Phase 1 program.

Eilean Therapeutics LLC announced the initiation of human dosing in the Phase 1 clinical program of ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.